Welcome to our dedicated page for Lexaria Bioscien news (Ticker: LEXXW), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscien stock.
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. (NASDAQ:LEXX, NASDAQ:LEXXW) is a global innovator in drug delivery technology, specializing in its patented DehydraTECH™ platform. This groundbreaking technology enhances the way active pharmaceutical ingredients (APIs) are absorbed into the bloodstream, offering faster onset times, improved bioavailability, and reduced side effects. DehydraTECH is applicable across a wide range of APIs, including cannabinoids, antiviral drugs, nicotine, and GLP-1 receptor agonists, making it a versatile solution in the pharmaceutical and biotechnology industries.
Core Technology: DehydraTECH™
DehydraTECH™ is a patented drug delivery formulation and processing platform that optimizes the oral delivery of APIs. By improving bio-absorption rates—up to 27 times higher for cannabinoids in some cases—and reducing onset times from hours to minutes, the technology addresses critical challenges in drug delivery. It has also demonstrated the ability to facilitate the transport of APIs across the blood-brain barrier, a significant advantage for treating neurological conditions.
Market Applications
Lexaria’s technology is particularly impactful in high-growth markets:
- GLP-1 Drugs: DehydraTECH has shown promise in enhancing the oral delivery of GLP-1 receptor agonists like semaglutide, liraglutide, and tirzepatide, which are used to treat diabetes, obesity, and cardiovascular diseases. By enabling oral formulations, Lexaria aims to replace the widely disliked injectable versions of these drugs.
- Neurological Disorders: The technology's ability to cross the blood-brain barrier positions it as a valuable tool in treating conditions like epilepsy and Alzheimer’s disease.
- Cannabinoids: DehydraTECH optimizes the delivery of cannabinoids for therapeutic applications, including pain management and seizure mitigation.
Business Model and Revenue Streams
Lexaria operates through four primary segments:
- Intellectual Property Licensing: The company licenses its technology to pharmaceutical and nutraceutical companies, generating recurring revenue.
- B2B Production: Lexaria produces DehydraTECH-enhanced formulations for business partners.
- Research and Development: The company conducts extensive R&D to expand its technology’s applications and validate its efficacy.
- Corporate Operations: This includes strategic planning and partnerships to drive growth.
Competitive Landscape
In the GLP-1 drug market, Lexaria competes with pharmaceutical giants like Novo Nordisk and Eli Lilly. However, its ability to deliver APIs effectively through oral formulations offers a distinct competitive edge. The company’s focus on reducing gastrointestinal side effects and improving patient compliance further strengthens its market position.
Intellectual Property
Lexaria boasts a robust intellectual property portfolio with 48 granted patents and numerous pending applications worldwide. These patents cover a wide range of applications, from epilepsy treatment to GLP-1 drug delivery, reinforcing the company’s authority in drug delivery innovation.
Research and Development
Lexaria operates a licensed in-house research laboratory, conducting preclinical and clinical studies to validate its technology. Recent studies have shown promising results in enhancing the performance of GLP-1 drugs, cannabinoids, and antiviral formulations. The company is also exploring new applications in cardiovascular and neurological health.
Geographical Reach
Lexaria generates revenue primarily from the United States and Canada, with plans to expand its global footprint through strategic partnerships and licensing agreements.
Conclusion
Lexaria Bioscience Corp. is at the forefront of drug delivery innovation, leveraging its patented DehydraTECH™ technology to address critical challenges in the pharmaceutical industry. By enabling more effective oral formulations, the company is poised to disrupt markets dominated by injectable drugs, offering significant benefits to patients and healthcare providers alike.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) announces that its patented DehydraTECH-CBD has shown enhanced effectiveness compared to Epidiolex in animal studies. The initial pilot study indicated that at lower doses of 50 mg/kg and 75 mg/kg, DehydraTECH-CBD was more effective than Epidiolex in reducing seizure activity. The secondary study revealed faster onset of action for DehydraTECH-CBD, with effective results observed at 30 and 60 minutes post-dosing. Lexaria plans to continue optimizing DehydraTECH-CBD formulations and conducting further studies to establish definitive dosing metrics.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) is set to launch its study program DEM-A22-1 on November 15, 2022, investigating DehydraTECH-processed CBD for potential therapeutic effects against dementia. Previous studies have shown CBD's efficacy in managing hypertension, a risk factor for vascular dementia. The upcoming study will include 32 Long Evans rats and aims to assess cognitive performance through a novel object recognition test. Results are anticipated in April 2023. The dementia treatment market is projected to grow from $15.5 billion in 2021 to $32.3 billion by 2030.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) has launched study DIAB-A22-1 to explore the therapeutic potential of its DehydraTECH-processed CBD for diabetes. The research involves 32 male Zucker rats over 56 days to assess weight gain, blood glucose, cholesterol, and triglyceride levels. Lexaria's technology has previously shown promise in hypertension. The diabetes market is significant, with global device and drug markets estimated at $26.7 billion and $63.1 billion, respectively. Results from the study are expected in early January 2023.
Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) announced IRB approval for its upcoming human clinical study NIC-H22-1, comparing its DehydraTECH-nicotine pouch to leading brands ON! and Zyn. The 36-person study will evaluate various metrics, including nicotine absorption and user experience. Previous studies indicate DehydraTECH technology may enhance nicotine delivery, achieving up to 20x faster absorption. With the oral nicotine pouch market projected to grow from $2.33 billion in 2020 to $21.84 billion by 2027, Lexaria aims to capitalize on this trend with its patented technology.
Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) announced positive results from its human clinical study HYPER-H21-4, demonstrating significant and sustained blood pressure (BP) reductions in hypertensive patients using its DehydraTECH-CBD formulation. Key findings include an average systolic BP reduction of up to 7.01 mmHg over five weeks, with no serious adverse events reported. The study suggests potential additive BP lowering effects for patients on standard medications. Lexaria plans to advance into a Phase Ib clinical study with the U.S. FDA.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) announced the appointment of Dr. Catherine Turkel to its board of directors, enhancing its leadership at a pivotal time. Dr. Turkel brings over 20 years of experience in the pharma and biotech sector, notably leading global drug development programs. Her expertise in regulatory strategy and commercial planning, particularly with Allergan's BOTOX program, is expected to advance Lexaria's DehydraTECH technology, which enhances the delivery of active pharmaceutical ingredients. Lexaria is positioned for continued growth following a successful pre-IND meeting with the FDA.
Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) announced the granting of its 27th international patent in Mexico under registration #390001. This patent is part of Lexaria's third patent family, covering Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Agents, which has also received recognition in Australia, India, and Japan. The patent allows the use of DehydraTECH-processed non-psychoactive cannabinoids to treat various disorders, including hypertension and neurological diseases. Lexaria continues its regulatory pursuit for DehydraTECH-CBD in pharmaceutical applications.
Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) recently provided insights on third-party valuation methods for biotech firms. Highlighting the lengthy and costly drug development process, the company noted that its DehydraTECH-CBD program is advancing through FDA's clinical research phase. Valuation metrics show significant potential for drugs in different clinical trial phases, with estimated valuations of $88 million, $248 million, and $1.12 billion at the start of Phase I, II, and III, respectively. Lexaria indicated that pursuing the FDA's 505(b)(2) regulatory pathway could enhance approval prospects.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced the successful completion of dosing in its clinical hypertension study, HYPER-H21-4, involving 64 patients. The study was randomized, double-blind, and placebo-controlled, aimed at assessing the safety and efficacy of DehydraTECH-CBD. Notably, no serious adverse events were reported, marking a significant safety milestone. The findings are anticipated to support an IND application to the FDA for further clinical testing. Secondary outcomes will include various cardiovascular health metrics, brain function, and overall health assessments, with data analyses expected to begin in September.
Lexaria Bioscience Corp. has issued a five-year, non-exclusive DehydraTECH license to AnodGen Bioceuticals for the European, Australian, and New Zealand markets. The license allows AnodGen to manufacture and distribute cannabinoid active pharmaceutical ingredient powders and mandates royalty payments to Lexaria for all sales. This partnership aims to enhance bioavailability and absorption of cannabinoid products. AnodGen plans to operationalize its facility in Ireland by the end of 2022, aiming for significant growth in the pharmaceutical sector.
FAQ
What is the current stock price of Lexaria Bioscien (LEXXW)?
What is Lexaria Bioscience Corp. known for?
What is DehydraTECH™?
What markets does Lexaria target?
How does Lexaria generate revenue?
What are Lexaria's competitive advantages?
What is Lexaria’s role in the GLP-1 drug market?
How many patents does Lexaria hold?
Where does Lexaria operate?
What recent achievements has Lexaria made?
What is Lexaria’s vision for the future?
